Literature DB >> 10616242

Tricuspid valve replacement: bioprostheses are preferable.

M J Dalrymple-Hay1, Y Leung, S K Ohri, M P Haw, J K Ross, S A Livesey, J L Monro.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Tricuspid valve replacement (TVR) is rarely undertaken, most surgeons preferring to use conservative tricuspid valve procedures. Thus, limited data are available in patients following TVR. The purpose of this study was to analyze the early and late results in 87 patients (52 tissue valves, 35 mechanical prostheses) who underwent TVR between January 1973 and September 1996.
METHODS: The patient group comprised 74 (85%) females and 13 (15%) males; mean (+/- SD) age was 59.4 +/- 12.8 years; range: 15 to 81 years). Forty-four patients (51%) had undergone at least one previous cardiac operation. There were 19 (23%) isolated TVRs, 43 (49%) triple valve replacements, and 25 (29%) double valve replacements. Total cumulative follow up was 707 patient-years (pt-yr) (tissue valves 393 pt-yr, mechanical valves 314 pt-yr); mean follow up was 8.1 years (range: 0 to 23.6 years).
RESULTS: The early (30-day) mortality rate was 10.3% (n = 9; tissue 7, mechanical 2, p = 0.28). Logistic regression identified prolonged cardiopulmonary bypass time (p <0.03) and advanced NYHA functional class (p <0.007) as risk factors for operative death. No risk factors were significant on multiple logistic regression analysis. Mean (+/- SEM) survival rate was 68 +/-5.3% (n = 50) at 5 years, 52 +/- 5.9% (n = 36) at 10 years, 35 +/- 6% (n = 20) at 15 years, and 16 +/- 5.3% (n = 7) at 20 years. Freedom from tricuspid valve reoperation at 5, 10 and 15 years was 93 +/- 3.3% (n = 46), 83 +/- 5.8% (n = 33) and 71 +/- 2.8% (n = 17) respectively. Eleven patients required tricuspid valve reoperation: six mechanical valves (five for prosthetic valve thrombosis and one for mechanical failure secondary to pannus ingrowth), and five tissue valves (two for prosthetic valve endocarditis and three for prosthetic valve degeneration). Freedom from reoperation at 5, 10 and 15 years for tissue prostheses was 97 +/- 2.5%, 89 +/- 6.3% and it was 70 +/- 12%, and 86 +/- 7.4%, 74 +/- 9.9% and 68 +/-11% for mechanical prostheses. The mechanical prostheses required reoperation earlier after the initial surgery.
CONCLUSIONS: We recommend the use of a bioprosthesis in the tricuspid position because of its initial durability and low reoperation rate.

Entities:  

Mesh:

Year:  1999        PMID: 10616242

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  5 in total

Review 1.  A look at recent improvements in the durability of tissue valves.

Authors:  Takahiro Nishida; Ryuji Tominaga
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-01-24

2.  Long-term results of bioprosthetic tricuspid valve replacement: an analysis of 25 years of experience.

Authors:  Naoto Morimoto; Syunsuke Matsushima; Masaya Aoki; Soichiro Henmi; Naritomo Nishioka; Hirohisa Murakami; Tasuku Honda; Keitaro Nakagiri; Masato Yoshida; Nobuhiko Mukohara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-12-06

3.  Isolated Reoperative Tricuspid Valve Surgery: Outcomes and Risk Assessment.

Authors:  Tahir I Mohamed; Omar J Baqal; Abdulaziz A Binzaid; Hussam T AlHennawi; Abdulrahman R Barakeh; Omar M Mrayati; Aly M Alsanei
Journal:  J Saudi Heart Assoc       Date:  2022-01-05

4.  Prosthetic tricuspid valve thrombosis: three case reports and literature review.

Authors:  Ahmad Yaminisharif; Mohammad Javad Alemzadeh-Ansari; Seyed Hossein Ahmadi
Journal:  J Tehran Heart Cent       Date:  2012-11-30

Review 5.  Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis.

Authors:  Pankaj Kaul; Krishna Adluri; Kalyana Javangula; Wasir Baig
Journal:  J Cardiothorac Surg       Date:  2009-02-24       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.